[1]吴国明,钱桂生.晚期非小细胞肺癌EGFR-TKIs治疗的耐药机制研究——挑战中蕴含新的曙光[J].第三军医大学学报,2012,34(20):2031-2034.
 Wu Guoming,Qian Guisheng.Drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in treatment of advanced non-small cell lung cancer—A new dawn in challenge[J].J Third Mil Med Univ,2012,34(20):2031-2034.
点击复制

晚期非小细胞肺癌EGFR-TKIs治疗的耐药机制研究——挑战中蕴含新的曙光(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
34卷
期数:
2012年第20期
页码:
2031-2034
栏目:
专家述评
出版日期:
2012-10-30

文章信息/Info

Title:
Drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in treatment of advanced non-small cell lung cancer—A new dawn in challenge
作者:
吴国明钱桂生
第三军医大学新桥医院呼吸内科,全军呼吸内科研究所,全军呼吸病研究重点实验室
Author(s):
Wu Guoming Qian Guisheng
Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
关键词:
晚期非小细胞肺癌EGFR-TKIs耐药
Keywords:
advanced non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitors resistance
分类号:
R734.2;R915;R979.1
文献标志码:
A
Abstract:
Currently, molecularly target therapy has increasingly altered the strategies in advanced non-small cell lung cancer (NSCLC). Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, are regarded as the most successful target drugs. However, EGFR-TKIs resistance has become a major clinical challenge. EGFR-TKIs resistance includes the primary resistance and the acquired resistance. The primary resistance’s mechanisms are associated with other non-sensitive EGFR mutations such as exon 20 insertions and other gene mutations such as KRAS, BRAF and EML4-ALK. The acquired resistance’s mechanisms are often associated with the secondary T790 mutation and MET gene amplification. At present, new strategies in overcoming EGFR-TKIs resistance are mainly focusing on irreversible EGFR inhibitors and MET inhibitors.

参考文献/References:

吴国明, 钱桂生. 晚期非小细胞肺癌EGFR-TKIs治疗的耐药机制研究——挑战中蕴含新的曙光[J]. 第三军医大学学报,2012,34(20):2031-2034.

相似文献/References:

[1]邵克锐,王建春.吉西他滨与紫杉醇联合奈达铂治疗晚期非小细胞肺癌的疗效及毒性反应观察[J].第三军医大学学报,2012,34(14):1450.
 Shao Kerui,Wang Jianchun.Efficiency and toxic reaction of nedaplatin combined with gemcitabine or paclitaxel in treatment of advanced non-small cell lung cancer: report of 133 cases[J].J Third Mil Med Univ,2012,34(20):1450.
[2]方向,胡世莲,沈干,等.吉西他滨联合顺铂方案与多西紫杉醇联合顺铂方案治疗晚期非小细胞肺癌的系统评价[J].第三军医大学学报,2010,32(21):2347.
 Fang Xiang,Hu Shilian,Shen Gan,et al.Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin:a systematic review[J].J Third Mil Med Univ,2010,32(20):2347.
[3]张岩巍,刘友如,张雪艳,等.107例经EGFR-TKIs一线治疗的非小细胞肺癌患者血肿瘤标记物水平与疗效的关系[J].第三军医大学学报,2012,34(20):2051.
 Zhang Yanwei,Liu Youru,Zhang Xueyan,et al.Relationship between tumor marker levels and efficacy of EGFR-TKIs first-line treatment in non-small cell lung cancer patients[J].J Third Mil Med Univ,2012,34(20):2051.

更新日期/Last Update: 2012-10-18